Showing 1–24 of 24 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Tushar R. Sahasrabudhe
…tional TB Elimination Programme (NTEP) has fixed 2HREZ/4HRE regimen for all drug-sensitive (DS-TB) cases, comprising of isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z). These potent first-line drugs, i.e., HREZ, are the backbone of DS-TB treatment for last man…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
…TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been …
Girase R, Ahmad I, Patel H
…against M. tuberculosis and is a crucial constituent of the BPaL regimen (Bedaquiline, Pretomanid, and Linezolid), which was authorized by the FDA in 2019 for the treatment of XDR-TB or MDR-TB. Despite its unique mechanism of action, Linezolid carries a considerable risk of toxic…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Oki Nugraha Putra, Telly Purnamasari
…red either a shorter (9 months) or individualized treatment regimen (18 months). However, long treatment duration with various adverse events affects patient compliance. Therefore, a short treatment with less medication is urgently required. In 2022, the WHO announced an alternat…
Tushar Garg
…reatments for complicated multidrug-resistant tuberculosis (MDR-TB) and extensive drug-resistant tuberculosis (XDR-TB), it will be challenging to achieve the World Health Organization (WHO) goal to end the global TB epidemic by 2035. The treatment of MDR- and XDR-TB consists of 4…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed the risk factors for unfavorable outcomes (death, treatment failure, and…
Zarir F Udwadia, Jigneshkumar M. Patel
…ease in the number of cases of TB and multi-drug resistant (MDR-TB) has unravelled decades of progress and reflects the profound impact COVID-19 has had on tuberculosis. Despite this grim news, these are exciting times for doctors treating Drug Resistant TB (DR-TB) and for their …
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
… of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom re…
Kavitha Saravu, Madhukar Pai
…ant TB (RR-TB), and 82% of them had multidrug-resistant TB (MDR-TB); 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB. A quarter of the DR-TB cases globally were from India.[1] Only about 25% of these estimated MDR-TB or RR-TB were diagnosed and notified. Th…
George Ikpe, Shadrach Dimang, Ufuoma Aduh, Peter Idowu Omoniyi, Ugochukwu Chukwulobelu, et al.
…CTION:** the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, …
Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, et al.
…ew treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in t…
Rafael Laniado-Laborı́n
…l or molecular tests for standardized drug sensitivity. Any regimen for drug-resistant TB is more likely to be effective if its composition is based on information from reliable drug susceptibility testing. The presence of drug-resistant tuberculosis should be suspected in patien…
Bruning-Barry R, Ambroso JL, Dillberger J, Yang TJ
…in more than 10 countries as part of a three-drug, all oral regimen, consisting of bedaquiline, pretomanid, and linezolid (BPaL) for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis (XDR-TB) or with complicated forms of multidrug-resistant tuber…
Christoph Lange, Yousra Kherabi, Lorenzo Guglielmetti, Raquel Duarte, Gunar Günther
…G. et al. “Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe”, published in this journal ( 1 Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group. Availability of drugs and…
Galo A. Goig, Chloé Loiseau, Nino Maghradze, Kakha Mchedlishvili, Teona Avaliani, et al.
Abstract Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB are threatening global TB control. The World Health Organization has recently endorsed new regimens for the treatment of MDR-TB that rely on the new and repurposed drugs bedaquiline, pretom…
Shaikh M, Patel H
…nificant global health challenge, with multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains posing severe threats to treatment efficacy. Linezolid, a key component of the BPaL (Bedaquiline, Pretomanid and Linezolid) regimen, has demonstrated substantial ef…
Karthick Vedi, N Venkateswaramurthy, P. Dineshkumar, Satheesh Nagendrans
…resistant tuberculosis (TB), including multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), poses major global health challenges. Conventional regimens achieve only 50-60% success rates compared to 85% in drug-susceptible TB. This review examines recent therap…
Anjali Krishnan P, Praveen Kumar N, Raghul Raj S, Ankit Kumar Bharti S, J. A. Pulatov
…TB Control Program. Results: Among 163 patients, short-term regimens were used in 30 patients (18.2%), including m-STTR (8.5%), m-STTR with delamanide (1.2%), and 6-month BPaLM (8.5%). Long-term standard regimens were used in 53 patients (32.5%). For XDR-TB, BPaL and BPaLC were u…
Nataliia Lytvynenko, Maryna Pogrebna, Yuliia Senko, Yurii Gamazin, Iana Terleeva
BPaL implementation started in Ukraine in November 2020, with the National Institute for TB and Lung Diseases (TB Institute), under TB Reach “Pilot Study to Evaluate the Effectiveness and Safety of the BPaL Treatment Regimen in Ukraine” project implemented by Organization for App…
Stancil SL, Mirzayev F, Abdel-Rahman SM
…States Food and Drug Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and recommended by the World Health Organization (WHO) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through th…
O.B. Pikas, M.A. Semeniuk
…0—45 %. The inclusion of second-line drugs in the treatment regimen of patients with isoniazid-resistant tuberculosis increases the effectiveness of treatment by 11.8 %. The overall effectiveness of treatment of patients with multidrug-resistant tuberculosis (MDR-TB) in the wor…
Preeti Preeti, Ameeta Joshi, Madhuparna Dev
…ezolid, and 11.1% were resistant. Linezolid sensitivity for MDR-TB patients was 88.72% of the cases being sensitive, and 11.28% resistant. Linezolid sensitivity in pre-extensively drug-resistant tuberculosis was 88.27% and 11.73% were resistant. Among 1031 samples, 50 samples tak…